Our approach
What is the GLP-1 weight management program?
At DGB Clinic, we understand that menopause-related changes in weight and body shape are influenced by biology, not willpower alone.
Our medical program may include GLP-1 receptor agonists, such as semaglutide or tirzepatide, prescribed and monitored by our physicians as part of a personalized plan for appetite, blood sugar and metabolic health.
Treatment time:
45 to 60 min; program lasting 3 to 12 months
Downtime:
No downtime. Resume daily activities right away.
benefits
Treatment goals
Targeted metabolic support
GLP-1-based medicines affect appetite and fullness and slow stomach emptying, which can support a gradual reduction in food intake.
The technique:
Treatment is self-injected under the skin once a week, with doses increased gradually as appropriate. Your plan takes medical history, body mass index and goals into account.
Benefits:
May reduce abdominal and visceral fat.
May improve blood sugar and cardiometabolic measures.
Clinical trials report average weight loss of about 14% to 22% with certain medicines and treatment plans.
Can be considered during perimenopause or menopause when medically appropriate.
Personalized medical monitoring.
effects & longevity
Expected results
Immediate effect
Changes in appetite may appear in the first weeks. Weight loss can become measurable after the first month, though individual results vary.
Evolution :
In STEP and SURMOUNT clinical trials, average weight loss ranged from about 14% to 22% of starting weight over 12 to 18 months, depending on the medicine and study. Individual results vary.
Duration:
The program may last three to twelve months, depending on your goals. Ongoing habits and follow-up care can help sustain results.
FAQ
Clinique%20DGB%20Bromont%202026-16.jpg)
